STOCK TITAN

Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Agios Pharmaceuticals, Inc. (AGIO) will host a conference call and live webcast to report its Q4 and year-end 2023 financial results and business highlights on February 15, 2024. The company specializes in cellular metabolism therapies for rare diseases and is a Nasdaq-listed leader in the field. The live webcast can be accessed on the company's website, with a replay available for at least two weeks.
Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 15, 2024, at 8:00 a.m. ET to report its fourth quarter and year end 2023 financial results and other business highlights.

A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.

About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency and MDS-associated anemia. In addition to its clinical pipeline, Agios has TMPRSS6 siRNA as a potential treatment for polycythemia vera, a PAH stabilizer in preclinical development as a potential treatment for phenylketonuria (PKU), and deep scientific expertise in classical hematology. For more information, please visit the company’s website at www.agios.com.

Contacts:

Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com

Media Contact
Dan Budwick
1AB
dan@1abmedia.com  


FAQ

When will Agios Pharmaceuticals, Inc. host the conference call and live webcast for its Q4 and year-end 2023 financial results?

Agios Pharmaceuticals, Inc. will host the conference call and live webcast on Thursday, February 15, 2024, at 8:00 a.m. ET.

What is the ticker symbol for Agios Pharmaceuticals, Inc.?

The ticker symbol for Agios Pharmaceuticals, Inc. is AGIO.

Where can the live webcast of the presentation be accessed?

The live webcast of the presentation can be accessed under 'Events & Presentations' in the Investors section of the company's website at www.agios.com.

How long will the replay of the webcast be available on the company's website?

A replay of the webcast will be archived on the company’s website for at least two weeks following the presentation.

Agios Pharmaceuticals, Inc.

NASDAQ:AGIO

AGIO Rankings

AGIO Latest News

AGIO Stock Data

3.10B
55.12M
1.51%
106.87%
7.61%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE